I have been under Dr Verter's care for a couple years after a torn retina. He and his team in Westport have been rockstars! Kudos to all!!! 👏👏👏👏
Anti-Inflammatory Medications for Retinal Conditions
Understanding Retinal Inflammation
Retinal inflammation can arise from many causes, and even a mild, ongoing inflammatory process can lead to meaningful vision loss over time. Knowing how inflammation affects the eye is an important first step in understanding why early treatment matters.
The retina is a thin layer of tissue at the back of the eye that converts light into the signals your brain reads as vision. When inflammation develops in or around the retina, it sets off a harmful chain of events. Fluid can accumulate in the macula (the central part of the retina responsible for sharp, detailed vision). Blood vessels may begin to leak. The photoreceptors, which are the specialized cells that capture light, can become damaged over time.
These changes can cause blurred or distorted vision. When inflammation continues without treatment, it can lead to lasting harm. Identifying and managing inflammation early gives your retina the best chance of staying healthy.
Prostaglandins are chemicals the body produces from a fatty acid called arachidonic acid. Inside the eye, prostaglandins disrupt the blood-ocular barrier (a protective layer that controls what enters the eye), widen blood vessels, and attract immune cells into the area. They also amplify other inflammatory signals, including vascular endothelial growth factor (VEGF), a protein that drives abnormal blood vessel growth and fluid leakage into the retina.
By blocking prostaglandin production, anti-inflammatory medications can reduce swelling, limit vascular leakage, and help stabilize the retinal environment.
Several common retinal conditions have a significant inflammatory component. These include diabetic macular edema (DME, or swelling in the central retina caused by diabetes), macular edema from retinal vein occlusion (RVO, a blockage in one of the veins that drains blood from the retina), and noninfectious uveitis (inflammation inside the eye not caused by infection) affecting the back of the eye. Cystoid macular edema (CME, a specific pattern of fluid buildup in the macula) can also develop after cataract surgery. Age-related macular degeneration (AMD) is another condition in which inflammation plays a role in how the disease progresses.
Who Is at Risk for Retinal Inflammation
Certain health conditions and medical histories increase the likelihood that inflammation will affect the retina. Understanding these risk factors can help guide how often your eyes should be monitored and whether preventive measures are appropriate for you.
A number of factors are associated with a higher chance of developing retinal inflammation. Your retina specialist will consider your full medical history when evaluating your individual risk.
- Diabetes mellitus, which significantly raises the risk of inflammatory complications and macular edema, according to the American Academy of Ophthalmology
- A history of retinal vein occlusion, one of the strongest predictors of developing cystoid macular edema after cataract surgery
- Pre-existing uveitis or other autoimmune conditions
- Age-related macular degeneration
- Use of prostaglandin-based glaucoma eye drops before eye surgery
- A weakened immune system due to medications, cancer treatment, or infections such as HIV
Knowing your personal risk profile allows your care team to tailor a monitoring and treatment plan that fits your situation.
Cataract surgery is one of the most commonly performed procedures in the world and is generally very safe. Even so, some patients develop cystoid macular edema after the operation, where fluid collects in the layers of the macula and blurs central vision. An analysis of more than three million cataract surgeries performed in the United States found an overall rate of postoperative cystoid macular edema of approximately 0.8 percent, according to the American Academy of Ophthalmology.
Patients with a prior history of retinal vein occlusion, epiretinal membrane (a thin layer of scar tissue that can form over the macula), or preoperative use of prostaglandin eye drops carry a notably higher risk. For these individuals, a retina specialist may recommend anti-inflammatory medications before or after surgery as a preventive measure.
Diabetes is one of the leading causes of preventable vision loss worldwide. Diabetic retinopathy, a common complication of both type 1 and type 2 diabetes, involves progressive damage to the small blood vessels in the retina. This damage triggers an inflammatory response that can lead to fluid leakage and macular swelling. Diabetic macular edema is the most common diabetes-related cause of vision loss. Keeping blood sugar well controlled and maintaining regular appointments with a retina specialist are among the most important steps for anyone living with diabetes.
Types of Anti-Inflammatory Medications
Two main categories of anti-inflammatory medication are used to treat retinal conditions: nonsteroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Each works through a different mechanism and is best suited to specific situations. Your retina specialist will recommend the approach that matches your diagnosis and the severity of your condition.
NSAIDs work by blocking the enzymes that produce prostaglandins. By reducing prostaglandin levels, these medications help decrease pain, light sensitivity, and inflammation. In eye care, NSAIDs are most commonly used as topical eye drops. Available options include ketorolac, diclofenac, nepafenac, bromfenac, and flurbiprofen, each with slightly different properties.
Nepafenac ophthalmic suspension is an example of a prodrug formulation, meaning it converts into its active form only after it enters the eye. This design may allow it to penetrate retinal tissue more effectively than older NSAID formulations.
Topical NSAIDs are most often prescribed around the time of cataract surgery. They help manage pain, reduce light sensitivity, prevent the pupil from narrowing during the procedure, and lower the risk of postoperative cystoid macular edema. Newer NSAID formulations have also generated interest in whether topical drops might play a role in managing other retinal conditions involving mild inflammation. For more serious retinal disease, however, the primary treatment approach involves intravitreal (inside-the-eye) delivery rather than drops alone.
Corticosteroids are powerful anti-inflammatory and immunosuppressive (immune-quieting) medications. Unlike NSAIDs, which target only prostaglandins, corticosteroids block multiple inflammatory pathways at once. They inhibit an enzyme called phospholipase A2, which prevents the production of both prostaglandins and leukotrienes (another group of inflammatory chemicals). They also suppress immune cell activity and reduce the signals that cause blood vessel leakage in the retina.
Corticosteroids also help strengthen the blood-retina barrier, the protective layer that prevents fluid and harmful substances from entering retinal tissue. This makes them especially effective at reducing macular edema in conditions such as DME, RVO, and uveitis.
The protective barriers of the eye prevent most medications from reaching the retina at effective concentrations through drops alone. For serious retinal conditions, corticosteroids are delivered directly into or near the eye using one of several methods.
- Intravitreal implants: small devices placed inside the vitreous cavity (the gel-filled space inside the eye) that slowly release medication over weeks or months
- Intravitreal injections: medication delivered directly into the vitreous cavity during a brief in-office procedure
- Intracameral injections: medication placed in the anterior chamber (the front section of the eye) at the end of cataract surgery
Your retina specialist will recommend the delivery method best suited to your specific condition and its severity.
Specific Medications Used in Retinal Care
Several FDA-approved corticosteroid treatments are currently used in retinal care. Each has a distinct formulation, duration of action, and set of approved indications. The most appropriate choice depends on your diagnosis, medical history, and how your eye has responded to previous treatments.
Ozurdex is a small, biodegradable implant placed inside the eye during a brief in-office procedure. It slowly releases dexamethasone, a corticosteroid, into the vitreous cavity over several weeks. Because it is biodegradable, the implant dissolves on its own and does not need to be surgically removed. The FDA has approved Ozurdex for three indications: macular edema following branch or central retinal vein occlusion, noninfectious uveitis affecting the posterior (back) segment of the eye, and diabetic macular edema.
Because it biodegrades, Ozurdex typically needs to be replaced every few months depending on how a patient responds and what condition is being treated. Your retina specialist will monitor your eye pressure and vision at each follow-up visit to determine the right timing for re-treatment.
Iluvien and Yutiq are long-acting implants that release fluocinolone acetonide, a low-dose corticosteroid, in a slow, controlled manner over an extended period. Iluvien is FDA-approved for diabetic macular edema in patients who have previously received a corticosteroid and did not experience a clinically significant rise in eye pressure. Yutiq is approved for chronic noninfectious uveitis affecting the posterior segment of the eye.
Both implants are designed to deliver steady medication levels for up to three years. This makes them a practical option for patients with persistent or recurrent inflammatory conditions who would otherwise require frequent office visits for repeat injections.
Triamcinolone acetonide is an injectable corticosteroid that a retina specialist can administer directly into the vitreous cavity. It is used to treat macular edema related to diabetic retinopathy, retinal vein occlusion, and uveitis. While effective, triamcinolone requires repeat injections over time as the medication clears from the eye. Like other corticosteroids used inside the eye, it carries the risk of elevated intraocular pressure (the fluid pressure inside the eye) and accelerated cataract formation, both of which are monitored closely at follow-up appointments.
Dexycu is a dexamethasone intraocular suspension designed specifically to treat inflammation following cataract surgery. At the end of the procedure, it is injected into the anterior chamber, where it forms a small reservoir that slowly releases dexamethasone over approximately 30 days. The FDA approved Dexycu in 2018. One practical advantage of this formulation is that it reduces or eliminates the need for a complex postoperative eye drop schedule, which some patients find difficult to follow consistently.
Anti-Inflammatory Therapy and Anti-VEGF Treatment
Anti-VEGF injections and anti-inflammatory medications are two distinct treatment strategies for retinal conditions. Understanding how they differ, and how they can complement each other, helps patients participate more fully in their care decisions.
Anti-VEGF agents such as aflibercept (Eylea) and faricimab (Vabysmo) work by blocking the VEGF protein that drives abnormal blood vessel growth and leakage. These medications are used primarily for wet age-related macular degeneration, diabetic macular edema, and macular edema from retinal vein occlusion. Anti-inflammatory medications target the broader inflammatory process, including prostaglandins, leukotrienes, and multiple immune signaling pathways. Both approaches aim to reduce fluid in the retina and protect vision, but they do so through different mechanisms.
In conditions such as diabetic macular edema, a retina specialist may choose between these therapies or use them in combination. Corticosteroids are sometimes considered when anti-VEGF injections alone have not adequately controlled macular swelling. The decision always depends on how a patient is responding and their individual health factors. It is also important to note that anti-VEGF injections used for wet AMD are not a treatment for dry AMD, which is a separate condition with its own management approach.
Some newer retinal medications have been associated with inflammatory side effects that require careful monitoring. Brolucizumab (Beovu), an anti-VEGF agent approved for wet age-related macular degeneration, has in some patients been linked to retinal vasculitis, which is inflammation of the blood vessels inside the retina. This is a rare but serious complication that retina specialists watch for closely during follow-up visits.
The American Society of Retina Specialists has also documented cases of occlusive retinal vasculitis (blockage of retinal blood vessels due to inflammation) following injection of pegcetacoplan (Syfovre), a complement inhibitor approved for geographic atrophy (the advanced form of dry age-related macular degeneration). These events were observed within roughly one to two weeks after injection. These reports highlight why monitoring after any intravitreal treatment is essential, and why anti-inflammatory management can become an important component of a broader retinal care plan.
What to Expect During Treatment
If your retina specialist recommends an anti-inflammatory injection or implant, knowing what to expect before and after the procedure can ease anxiety and help you prepare. Most procedures take place in the office and require only a short visit.
Before the procedure, your eye will be numbed using anesthetic eye drops or a local anesthetic. The surface of the eye and surrounding skin will then be cleaned with an antiseptic solution to reduce the risk of infection. The preparation process is brief and is designed to keep you as comfortable as possible throughout.
During the injection or implant placement, you may feel a sensation of pressure but should not experience sharp pain. The procedure itself typically takes only a few minutes. Afterward, mild redness, discomfort, or a gritty feeling in the eye is common. These symptoms usually resolve within a day or two. Your care team may prescribe antibiotic eye drops for a short period after the procedure to help prevent infection.
For patients using topical NSAID drops around the time of cataract surgery, the regimen is straightforward. Drops are typically started one to two days before surgery and continued for several weeks afterward, according to the schedule your surgeon prescribes.
Anti-inflammatory medications given inside the eye require regular follow-up. Corticosteroids can raise intraocular pressure, which, if left undetected, may increase the risk of glaucoma (a condition where elevated pressure can damage the optic nerve over time). Corticosteroids may also accelerate cataract development. At each visit, your retina specialist will check your eye pressure, examine your retina, and assess how well the treatment is working. The plan can be adjusted based on how your eye responds over time.
Living With a Retinal Inflammatory Condition
Many retinal conditions that involve inflammation require ongoing care rather than a single course of treatment. Staying engaged with your care plan and knowing what to watch for between appointments are both important parts of protecting your vision over the long term.
Consistency is one of the most important factors in managing chronic retinal inflammation. Missing appointments or stopping medications early can allow inflammation to return and cause further damage. The goal of long-term treatment is to control inflammation and preserve as much vision as possible. Your retina specialist will work with you to find the right treatment interval and make adjustments as your condition changes over time.
There are practical steps patients can take between appointments to support their retinal health. For those with diabetes, keeping blood sugar as well controlled as possible is critical, since high blood sugar directly contributes to retinal inflammation and blood vessel damage. Taking all prescribed medications on schedule, including eye drops, helps maintain steady control of inflammation between office visits.
Wearing sunglasses outdoors can reduce UV light exposure to the eyes. A diet that includes leafy green vegetables, fish high in omega-3 fatty acids, and colorful fruits and vegetables may support general eye health. These lifestyle measures complement medical treatment but are not a substitute for it.
While routine monitoring is essential, certain symptoms should prompt you to seek care right away. Do not wait for a scheduled appointment if you experience any of the following:
- A sudden increase in floaters (spots, strings, or shadows drifting through your vision)
- New flashes of light in one or both eyes
- A dark shadow or curtain appearing at the edge of your vision or spreading inward
- Sudden blurred or distorted vision in one eye
- A rapid decrease in vision within days of a recent eye injection or procedure
Inflammation can develop or worsen even months after treatment has started. Some patients notice new floaters or a sudden change in clarity, while others may have no symptoms even when inflammation is active. If anything changes in your vision, contacting your retina specialist promptly is always the right step.
Frequently Asked Questions
These questions address common points of confusion and practical decisions patients face when managing retinal inflammation. The answers are intended to add context and decision guidance beyond what is covered in the sections above.
Both categories reduce inflammation, but they do so at different points in the inflammatory process and with different levels of potency. NSAIDs block a specific enzyme to reduce prostaglandin production, making them well-suited for managing inflammation around cataract surgery in drop form. Corticosteroids block multiple inflammatory pathways simultaneously, giving them broader reach against the sustained or severe inflammation seen in diabetic macular edema, retinal vein occlusion, and uveitis. Because corticosteroids are more powerful, they are associated with a higher risk of elevated eye pressure and cataract development, which is why they require closer monitoring. Your retina specialist will choose based on your diagnosis, how active the inflammation is, and your individual health history.
Yes, and this combination is sometimes the right clinical decision. When macular swelling does not respond fully to anti-VEGF injections alone, adding a corticosteroid addresses the broader inflammatory pathways that VEGF blockers do not directly target. This combined approach is not appropriate for every patient and requires careful evaluation of how your eye has responded and which side effect risks are most relevant to your medical history. Your retina specialist will guide this decision based on your individual situation rather than a fixed protocol.
The two most common concerns are elevated intraocular pressure and accelerated cataract formation. Elevated eye pressure, if not caught and managed, can contribute to glaucoma over time, which is why pressure checks are a routine part of every follow-up visit during corticosteroid treatment. Cataract progression is more likely with extended use, and if it becomes clinically significant, your care team will discuss next steps with you. These are manageable risks when monitored consistently, and they should not discourage you from pursuing treatment when it is genuinely indicated.
Duration varies depending on which implant is used. Ozurdex (dexamethasone) is biodegradable and releases medication over several weeks, typically requiring re-implantation every few months based on how a patient responds. Iluvien and Yutiq (fluocinolone acetonide) are designed for extended release lasting up to three years, making them better suited for patients with chronic or recurrent conditions who would otherwise need frequent injections. The right implant depends on the condition being treated, its severity, your prior response to corticosteroids, and how your intraocular pressure reacts to steroid exposure. Your retina specialist will weigh all of these factors when making a recommendation.
Topical NSAID drops are effective for managing inflammation around cataract surgery and for reducing the risk of postoperative cystoid macular edema in appropriate patients. For more serious retinal conditions such as diabetic macular edema, retinal vein occlusion, or posterior uveitis, drops alone are not sufficient. The structural barriers of the eye prevent topical medications from reaching the retina at concentrations needed to control active disease. These conditions require intravitreal injections or implants to deliver treatment directly to the affected tissue. If you are uncertain whether your current treatment is adequately addressing your condition, a consultation with a retina specialist is the appropriate next step.
Visit New England Retina Associates
At New England Retina Associates, our fellowship-trained vitreoretinal surgeons provide expert, individualized care for the full range of retinal inflammatory conditions throughout Connecticut. Our team brings the clinical depth, advanced diagnostics, and treatment experience needed to evaluate even complex cases and develop a plan tailored to your needs. Whether you have been referred by your eye doctor, are seeking a second opinion, or are experiencing sudden changes in your vision, we welcome you to schedule a visit at any of our four Connecticut offices.
30 Years of Care & Commitment
